"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A3,WO 2023/275617 A3,122-047-751-939-249,2023-02-09,2023,IB 2022000376 W,2022-06-29,US 202163217543 P,2021-07-01,DIAGNOSTIC AND TREATMENT MONITORING BASED ON BLOOD-BRAIN BARRIER DISRUPTION,"The disclosure provides technologies that permit detection and/or characterization of brain biomarkers ( e.g. , disease-associated biomarkers) in non-CNS samples, including by liquid biopsy ( e.g. , blood, serum, etc. ). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials ( e.g. , brain-derived proteins, neuron-derived extracellular vesicles, and/or cell-free DNA) in readily-sampled systemic liquids.",INSIGHTEC LTD,ACHROL ACHAL;;LEVY YOAV,,https://lens.org/122-047-751-939-249,Search Report,yes,1,0,3,3,0,G01N33/6896,G01N33/68,,11,11,046-452-303-680-581;;118-077-898-591-534;;021-391-323-430-906;;126-032-559-536-873;;048-959-259-732-828;;109-528-179-079-802;;038-539-011-295-229;;075-377-185-890-709;;011-249-983-490-023;;006-389-790-637-766;;013-944-498-993-441,33693781;;10.1093/neuonc/noab057;;pmc8485448;;pmc7198482;;10.1038/s41598-020-64440-3;;32366915;;pmc5919906;;29700310;;10.1038/s41598-018-24516-7;;pmc7269259;;32492056;;10.1371/journal.pone.0234182;;10.1158/1078-0432.ccr-20-3760;;34031054;;pmc9012394;;10.1007/s13311-018-00683-3;;pmc6361053;;30406382;;10.1016/j.ultrasmedbio.2009.03.012;;19545939;;pmc2729364;;pmc4668271;;26562661;;10.1088/0031-9155/60/23/9079;;10.1158/1078-0432.ccr-18-3643;;30890548;;31831565;;pmc7050644;;10.1158/1078-0432.ccr-19-2182;;10.1200/jco.2022.40.16_suppl.2016,"MENG YING ET AL: ""MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors"", NEURO-ONCOLOGY, vol. 23, no. 10, 10 March 2021 (2021-03-10), US, pages 1789 - 1797, XP055978651, ISSN: 1522-8517, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485448/pdf/noab057.pdf> DOI: 10.1093/neuonc/noab057;;PACIA CHRISTOPHER PHAM ET AL: ""Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model"", SCIENTIFIC REPORTS, vol. 10, no. 1, 1 December 2020 (2020-12-01), pages 7449, XP055978649, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-020-64440-3.pdf> DOI: 10.1038/s41598-020-64440-3;;ZHU LIFEI ET AL: ""Focused Ultrasound-enabled Brain Tumor Liquid Biopsy"", SCIENTIFIC REPORTS, vol. 8, no. 1, 26 April 2018 (2018-04-26), XP055978643, Retrieved from the Internet <URL:http://www.nature.com/articles/s41598-018-24516-7> DOI: 10.1038/s41598-018-24516-7;;ZHU LIFEI ET AL: ""Focused ultrasound for safe and effective release of brain tumor biomarkers into the peripheral circulation"", PLOS ONE, vol. 15, no. 6, 3 June 2020 (2020-06-03), pages 1 - 15, XP055978648, Retrieved from the Internet <URL:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0234182&type=printable> DOI: 10.1371/journal.pone.0234182;;SABBAGH ARIA ET AL: ""Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models"", CLINICAL CANCER RESEARCH, vol. 27, no. 15, 24 May 2021 (2021-05-24), US, pages 4325 - 4337, XP055978657, ISSN: 1078-0432, Retrieved from the Internet <URL:https://watermark.silverchair.com/4325.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtUwggLRBgkqhkiG9w0BBwagggLCMIICvgIBADCCArcGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMflB-XsFmqjkEUA3-AgEQgIICiG3zm_88wEsYl151wfd9KLEG7PPbwdDZJk6g6OA5ne2RuoKNuZiAUuEyRKhAFKWCBZ-dEKDj_6uPBp84sJ74ypyfDcLZjmi> DOI: 10.1158/1078-0432.CCR-20-3760;;PRADA FRANCESCO ET AL: ""Applications of Focused Ultrasound in Cerebrovascular Diseases and Brain Tumors"", NEUROTHERAPEUTICS, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 16, no. 1, 7 November 2018 (2018-11-07), pages 67 - 87, XP036927102, ISSN: 1933-7213, [retrieved on 20181107], DOI: 10.1007/S13311-018-00683-3;;BING K F ET AL: ""Blood-Brain Barrier (BBB) Disruption Using a Diagnostic Ultrasound Scanner and Definity(R) in Mice"", ULTRASOUND IN MEDICINE AND BIOLOGY, NEW YORK, NY, US, vol. 35, no. 8, 1 August 2009 (2009-08-01), pages 1298 - 1308, XP026321831, ISSN: 0301-5629, [retrieved on 20090709], DOI: 10.1016/J.ULTRASMEDBIO.2009.03.012;;TAO SUN ET AL: ""Acoustic cavitation-based monitoring of the reversibility and permeability of ultrasound-induced blood-brain barrier opening"", PHYSICS IN MEDICINE AND BIOLOGY, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL GB, vol. 60, no. 23, 12 November 2015 (2015-11-12), pages 9079 - 9094, XP020293692, ISSN: 0031-9155, [retrieved on 20151112], DOI: 10.1088/0031-9155/60/23/9079;;IDBAIH AHMED ET AL: ""Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma"", CLINICAL CANCER RESEARCH, vol. 25, no. 13, 1 July 2019 (2019-07-01), US, pages 3793 - 3801, XP093025645, ISSN: 1078-0432, Retrieved from the Internet <URL:https://watermark.silverchair.com/3793.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAzgwggM0BgkqhkiG9w0BBwagggMlMIIDIQIBADCCAxoGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMsRiwgnSPn24fACR5AgEQgIIC61hTC09iugnVQSIXmLT0WBE7mTpNLVtjsxb5VwgPuQcx456uADuvSaTd3I8gnXzkdPPolfHIbxfWs0FPNQlWj8XoisKxHWd> DOI: 10.1158/1078-0432.CCR-18-3643;;ZHANG DANIEL Y. ET AL: ""Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations"", CLINICAL CANCER RESEARCH, vol. 26, no. 2, 15 January 2020 (2020-01-15), US, pages 477 - 486, XP093025647, ISSN: 1078-0432, Retrieved from the Internet <URL:https://watermark.silverchair.com/477.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAzMwggMvBgkqhkiG9w0BBwagggMgMIIDHAIBADCCAxUGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMqwA0wSK1zLO6U5QlAgEQgIIC5uPT-AFO4mD2GwFLvdDZCaY24UN7tBnDE7KxrPDtDJkPtN7sRkwoxDtdBZwj7M_2P7r5hTfDBMwwMVs2VTJw_OoqkAuOL_s-> DOI: 10.1158/1078-0432.CCR-19-2182;;SONABEND ADAM M ET AL: ""Repeated opening of the blood-brain barrier with the skull-implantable SonoCloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma"", JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16 supplement, 1 June 2022 (2022-06-01), pages 2016 - 2016, XP093025648, Retrieved from the Internet <URL:https://d32wbias3z7pxg.cloudfront.net/meeting/288/abstract/pdf/288-14351-207623.pdf>",PENDING
2,WO,A2,WO 2023/275617 A2,030-402-727-839-844,2023-01-05,2023,IB 2022000376 W,2022-06-29,US 202163217543 P,2021-07-01,DIAGNOSTIC AND TREATMENT MONITORING BASED ON BLOOD-BRAIN BARRIER DISRUPTION,"The disclosure provides technologies that permit detection and/or characterization of brain biomarkers ( e.g. , disease-associated biomarkers) in non-CNS samples, including by liquid biopsy ( e.g. , blood, serum, etc. ). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials ( e.g. , brain-derived proteins, neuron-derived extracellular vesicles, and/or cell-free DNA) in readily-sampled systemic liquids.",INSIGHTEC LTD,ACHROL ACHAL;;LEVY YOAV,,https://lens.org/030-402-727-839-844,Patent Application,yes,2,0,3,3,4,G01N33/6896,G01N33/68,,1,1,001-038-163-674-756,10.1109/transducers.2017.7994114,"Z. CHENG ET AL.: ""International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS"", vol. 2017, 2017, article ""An emulsion digital PCR quantitative method based on microbeads and micropillar array chip"", pages: 575 - 578",PENDING
3,WO,A9,WO 2023/275617 A9,137-835-925-414-306,2023-04-13,2023,IB 2022000376 W,2022-06-29,US 202163217543 P,2021-07-01,DIAGNOSTIC AND TREATMENT MONITORING BASED ON BLOOD-BRAIN BARRIER DISRUPTION,"The disclosure provides technologies that permit detection and/or characterization of brain biomarkers ( e.g. , disease-associated biomarkers) in non-CNS samples, including by liquid biopsy ( e.g. , blood, serum, etc. ). Among other things, the present disclosure demonstrates that ultrasound opening of the blood brain barrier can achieve detectable increases in brain-derived materials ( e.g. , brain-derived proteins, neuron-derived extracellular vesicles, and/or cell-free DNA) in readily-sampled systemic liquids.",INSIGHTEC LTD,ACHROL ACHAL;;LEVY YOAV,,https://lens.org/137-835-925-414-306,Search Report,yes,0,0,3,3,0,G01N33/6896,G01N33/68,,0,0,,,,PENDING
4,US,A1,US 2023/0026732 A1,128-513-561-317-83X,2023-01-26,2023,US 202217872717 A,2022-07-25,US 202217872717 A;;US 202163225671 P,2021-07-26,Large Vessel Occlusion Alert from Optical Measurements,A first optical measurement of tissue with a first optical device is initiated. The first optical measurement includes a first shallow optical reading and a first deeper optical reading. A second optical measurement of the tissue with a second optical device spaced is initiated. The second optical device is spaced apart from the first optical device. The second optical measurement includes a second shallow optical reading and a second deeper optical reading. A first difference value between the first shallow optical reading and the first deeper optical reading is determined. A second difference value between the second shallow optical reading and the second deeper optical reading is determined. A large vessel occlusion (LVO) alert is generated when a ratio of the first difference value to the second difference value is larger than a threshold value.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN,OPEN WATER INTERNET INC (2022-08-04),https://lens.org/128-513-561-317-83X,Patent Application,yes,0,0,5,5,0,A61B5/0013;;A61B5/0022;;A61B5/02007;;A61B5/0261;;A61B5/1112;;A61B5/4064;;A61B5/6803;;A61B5/7275;;A61B5/746;;A61B5/0261;;A61B17/135;;A61B5/6803;;A61B5/4064;;A61B5/0013;;A61B5/0022;;A61B5/0082;;A61B5/02007;;A61B5/1112;;A61B5/7275;;A61B5/746;;G01C21/3626,A61B5/026;;A61B5/00,,0,0,,,,PENDING
5,WO,A1,WO 2010/132862 A1,036-743-700-940-591,2010-11-18,2010,US 2010/0035040 W,2010-05-14,US 17842909 P,2009-05-14,MICROFLUIDIC METHOD AND SYSTEM FOR ISOLATING PARTICLES FROM BIOLOGICAL FLUID,"The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.",GENESTREAM INC;;ACHROL ACHAL SINGH;;SETHU PALANIAPPAN,ACHROL ACHAL SINGH;;SETHU PALANIAPPAN,,https://lens.org/036-743-700-940-591,Patent Application,yes,5,4,4,4,0,B01L3/502753;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N33/54333;;G01N2015/1006;;G01N15/1459;;G01N15/149;;B01L3/502753;;G01N33/54333;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N2015/1006;;G01N15/1459;;G01N15/149;;A61K35/12;;B01L2300/0883;;B03C2201/18;;G01N27/745;;A61K35/14;;G01N33/53,C12M1/34;;G01N33/48,,0,0,,,,PENDING
6,WO,A8,WO 2023/009999 A8,050-043-571-701-403,2023-04-06,2023,US 2022/0074137 W,2022-07-26,US 202163225671 P;;US 202217872717 A,2021-07-26,LARGE VESSEL OCCLUSION ALERT FROM OPTICAL MEASUREMENTS,A first optical measurement of tissue with a first optical device is initiated. The first optical measurement includes a first shallow optical reading and a first deeper optical reading. A second optical measurement of the tissue with a second optical device spaced is initiated. The second optical device is spaced apart from the first optical device. The second optical measurement includes a second shallow optical reading and a second deeper optical reading. A first difference value between the first shallow optical reading and the first deeper optical reading is determined. A second difference value between the second shallow optical reading and the second deeper optical reading is determined. A large vessel occlusion (LVO) alert is generated when a ratio of the first difference value to the second difference value is larger than a threshold value.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN,,https://lens.org/050-043-571-701-403,Amended Application,yes,0,0,5,5,0,A61B5/0013;;A61B5/0022;;A61B5/02007;;A61B5/0261;;A61B5/1112;;A61B5/4064;;A61B5/6803;;A61B5/7275;;A61B5/746;;A61B5/0261;;A61B17/135;;A61B5/6803;;A61B5/4064;;A61B5/0013;;A61B5/0022;;A61B5/0082;;A61B5/02007;;A61B5/1112;;A61B5/7275;;A61B5/746;;G01C21/3626,A61B8/08;;A61B5/00;;A61B8/00;;G16H50/20;;H04N5/33,,0,0,,,,PENDING
7,US,A1,US 2023/0025985 A1,100-992-618-703-251,2023-01-26,2023,US 202217872652 A,2022-07-25,US 202217872652 A;;US 202163225671 P,2021-07-26,LARGE VESSEL OCCLUSION EARLY NOTIFICATION AND EMERGENCY MEDICAL ROUTING,A large vessel occlusion (LVO) alert generated by a point-of-care diagnostic system is received. The LVO alert is representative of a probability of an LVO event in a patient. A mapping coordinate is received. A database of care centers proximate to the mapping coordinate is accessed. A preferred care center from the database is selected based at least on a treatment capability associated with the preferred care center and a distance of the care centers to the mapping coordinate. An LVO event notification is transmitted to initiate stroke medical care.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN,OPEN WATER INTERNET INC (2022-08-04),https://lens.org/100-992-618-703-251,Patent Application,yes,0,0,5,5,0,A61B5/0013;;A61B5/0022;;A61B5/02007;;A61B5/0261;;A61B5/1112;;A61B5/4064;;A61B5/6803;;A61B5/7275;;A61B5/746;;A61B5/0261;;A61B17/135;;A61B5/6803;;A61B5/4064;;A61B5/0013;;A61B5/0022;;A61B5/0082;;A61B5/02007;;A61B5/1112;;A61B5/7275;;A61B5/746;;G01C21/3626,A61B5/00;;A61B5/02;;A61B5/11;;G01C21/36,,0,0,,,,PENDING
8,US,A1,US 2014/0302160 A1,172-636-637-070-008,2014-10-09,2014,US 201414312149 A,2014-06-23,US 201414312149 A;;US 77974610 A;;US 17842909 P,2009-05-14,MICROFLUIDIC METHOD AND SYSTEM FOR ISOLATING PARTICLES FROM BIOLOGICAL FLUID,"The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.",GENESTREAM INC,ACHROL ACHAL SINGH;;SETHU PALANIAPPAN,,https://lens.org/172-636-637-070-008,Patent Application,yes,5,10,4,4,0,B01L3/502753;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N33/54333;;G01N2015/1006;;G01N15/1459;;G01N15/149;;B01L3/502753;;G01N33/54333;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N2015/1006;;G01N15/1459;;G01N15/149;;A61K35/12;;B01L2300/0883;;B03C2201/18;;G01N27/745;;A61K35/14;;G01N33/53,G01N33/53;;A61K35/14,424/529;;435/7.21,0,0,,,,DISCONTINUED
9,US,A1,US 2011/0020459 A1,085-438-363-686-970,2011-01-27,2011,US 77974610 A,2010-05-13,US 77974610 A;;US 17842909 P,2009-05-14,Microfluidic method and system for isolating particles from biological fluid,"The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.",ACHROL ACHAL SINGH;;SETHU PALANIAPPAN,ACHROL ACHAL SINGH;;SETHU PALANIAPPAN,GENESTREAM INC (2014-06-11),https://lens.org/085-438-363-686-970,Patent Application,yes,100,48,4,4,0,B01L3/502753;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N33/54333;;G01N2015/1006;;G01N15/1459;;G01N15/149;;B01L3/502753;;G01N33/54333;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N2015/1006;;G01N15/1459;;G01N15/149;;A61K35/12;;B01L2300/0883;;B03C2201/18;;G01N27/745;;A61K35/14;;G01N33/53,A61K35/12;;C12M1/34;;G01N33/53,424/520;;435/7.21;;435/287.1,0,0,,,,INACTIVE
10,WO,A1,WO 2023/009999 A1,171-488-374-764-308,2023-02-02,2023,US 2022/0074137 W,2022-07-26,US 202163225671 P;;US 202217872717 A,2021-07-26,LARGE VESSEL OCCLUSION ALERT FROM OPTICAL MEASUREMENTS,A first optical measurement of tissue with a first optical device is initiated. The first optical measurement includes a first shallow optical reading and a first deeper optical reading. A second optical measurement of the tissue with a second optical device spaced is initiated. The second optical device is spaced apart from the first optical device. The second optical measurement includes a second shallow optical reading and a second deeper optical reading. A first difference value between the first shallow optical reading and the first deeper optical reading is determined. A second difference value between the second shallow optical reading and the second deeper optical reading is determined. A large vessel occlusion (LVO) alert is generated when a ratio of the first difference value to the second difference value is larger than a threshold value.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN,,https://lens.org/171-488-374-764-308,Patent Application,yes,3,0,5,5,0,A61B5/0013;;A61B5/0022;;A61B5/02007;;A61B5/0261;;A61B5/1112;;A61B5/4064;;A61B5/6803;;A61B5/7275;;A61B5/746;;A61B5/0261;;A61B17/135;;A61B5/6803;;A61B5/4064;;A61B5/0013;;A61B5/0022;;A61B5/0082;;A61B5/02007;;A61B5/1112;;A61B5/7275;;A61B5/746;;G01C21/3626,A61B8/08;;A61B5/00;;A61B8/00;;G16H50/20;;H04N5/33,,0,0,,,,PENDING
11,WO,A1,WO 2023/009998 A1,007-880-703-165-884,2023-02-02,2023,US 2022/0074133 W,2022-07-26,US 202163225671 P;;US 202217872652 A,2021-07-26,LARGE VESSEL OCCLUSION EARLY NOTIFICATION AND EMERGENCY MEDICAL ROUTING,A large vessel occlusion (LVO) alert generated by a point-of-care diagnostic system is received. The LVO alert is representative of a probability of an LVO event in a patient. A mapping coordinate is received. A database of care centers proximate to the mapping coordinate is accessed. A preferred care center from the database is selected based at least on a treatment capability associated with the preferred care center and a distance of the care centers to the mapping coordinate. An LVO event notification is transmitted to initiate stroke medical care.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN,,https://lens.org/007-880-703-165-884,Patent Application,yes,4,0,5,5,0,A61B5/0013;;A61B5/0022;;A61B5/02007;;A61B5/0261;;A61B5/1112;;A61B5/4064;;A61B5/6803;;A61B5/7275;;A61B5/746;;A61B5/0261;;A61B17/135;;A61B5/6803;;A61B5/4064;;A61B5/0013;;A61B5/0022;;A61B5/0082;;A61B5/02007;;A61B5/1112;;A61B5/7275;;A61B5/746;;G01C21/3626,G16H40/20;;A61B5/00;;G01C21/34;;G16H50/20,,0,0,,,,PENDING
12,US,B2,US 8790916 B2,021-312-743-404-984,2014-07-29,2014,US 77974610 A,2010-05-13,US 77974610 A;;US 17842909 P,2009-05-14,Microfluidic method and system for isolating particles from biological fluid,"The invention relates to a system and method for isolating particles from a biological fluid, including: obtaining a sample of biological fluid from a source (e.g. a patient) in which the sample contains particles of multiple sample particle types; tagging particles in the sample with tagging agents, including mixing the sample with a solution of magnetic tagging agents that selectively bind to particles of at least one of the sample particle types, thereby forming a group of tagged particles in the sample; passing the sample through a magnetic conduit having a magnetic field that interacts with at least some of the tagged particles; sorting the particles of the sample into multiple groups based on the interaction between the tagged particles and the magnetic field; and optionally returning selected portions of the processed fluid back to its source with or without the addition of appropriate therapeutic agents.",ACHROL ACHAL SINGH;;SETHU PALANIAPPAN;;GENESTREAM INC,ACHROL ACHAL SINGH;;SETHU PALANIAPPAN,GENESTREAM INC (2014-06-11),https://lens.org/021-312-743-404-984,Granted Patent,yes,112,6,4,4,0,B01L3/502753;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N33/54333;;G01N2015/1006;;G01N15/1459;;G01N15/149;;B01L3/502753;;G01N33/54333;;B01L2200/0652;;B01L2400/043;;G01N33/54326;;G01N2015/1006;;G01N15/1459;;G01N15/149;;A61K35/12;;B01L2300/0883;;B03C2201/18;;G01N27/745;;A61K35/14;;G01N33/53,C12M1/34;;A61K35/12;;G01N27/74,435/287.1;;436/526;;422/414,0,0,,,,INACTIVE
13,WO,A2,WO 2023/012516 A2,153-852-521-831-976,2023-02-09,2023,IB 2022000444 W,2022-08-02,US 202163229865 P,2021-08-05,COMPOSITIONS AND METHODS RELATED TO BLOOD-BRAIN BARRIER PENETRATION,The disclosure is directed to methods related to the delivery of antibodies targeting Her2 across the blood-brain barrier.,INSIGHTEC LTD;;SUNNYBROOK RES INST,ACHROL ACHAL;;LIPSMAN NIR;;MENG YING;;ALIKACEM NADIR,,https://lens.org/153-852-521-831-976,Patent Application,yes,0,0,2,2,1,A61M37/00;;A61M37/0092;;A61N2007/0039;;A61N7/00;;A61N2007/0026;;A61N2007/0065,,,0,0,,,,PENDING
14,WO,A3,WO 2023/012516 A3,135-228-004-790-801,2023-07-20,2023,IB 2022000444 W,2022-08-02,US 202163229865 P,2021-08-05,COMPOSITIONS AND METHODS RELATED TO BLOOD-BRAIN BARRIER PENETRATION,The disclosure is directed to methods related to the delivery of antibodies targeting Her2 across the blood-brain barrier.,INSIGHTEC LTD;;SUNNYBROOK RES INST,ACHROL ACHAL;;LIPSMAN NIR;;MENG YING;;ALIKACEM NADIR,,https://lens.org/135-228-004-790-801,Search Report,yes,4,0,2,2,0,A61M37/00;;A61M37/0092;;A61N2007/0039;;A61N7/00;;A61N2007/0026;;A61N2007/0065,A61M37/00;;A61N7/00,,0,0,,,,PENDING
15,US,A1,US 2012/0270331 A1,180-145-732-279-022,2012-10-25,2012,US 201213452760 A,2012-04-20,US 201213452760 A;;US 201161477482 P,2011-04-20,MICROFLUIDIC SYSTEM AND METHOD FOR AUTOMATED PROCESSING OF PARTICLES FROM BIOLOGICAL FLUID,"A microfluidic system for automatically depleting particles not of interest from a biological sample, comprising: a sampling module configured to receive the sample; and one or more microfluidic protein and nucleic acid depletion modules fluidically coupled to the sampling module and comprising binding agents configured to selectively bind to abundant plasma proteins or nucleic acids. A method for automatically depleting particles not of interest from a sample, comprising: receiving the sample; subjecting the sample to a force that separates at least a portion of the particles not of interest from the sample, thereby isolating at least a portion of the target component; passing the isolated target copmonent into a chamber; circulating the isolated target component in the chamber; and selectively capturing proteins or nucleic acids with binding agents within the chamber.",ACHROL ACHAL SINGH;;SETHU PALANIAPPAN;;GASTER RICHARD S,ACHROL ACHAL SINGH;;SETHU PALANIAPPAN;;GASTER RICHARD S,,https://lens.org/180-145-732-279-022,Patent Application,yes,2,22,1,1,0,B01L3/502761;;B01L3/502761;;B01L2200/0652;;B01L2200/0652;;B01L2300/0864;;B01L2300/0864;;B01L2400/043;;B01L2400/043;;B01L2400/0487;;B01L2400/0487;;G01N2001/4083;;G01N2001/4083;;Y10T436/25375;;Y10T436/25375,G01N1/18;;B01L3/00,436/177;;422/502,1,1,119-780-494-714-949,10.1016/s0021-9673(02)00160-7;;12058915,"P. Jandik, B.H. Weigl, N. Kessler, J. Cheng, C.J. Morris, T. Schulte, N. Avdalovic ""Initial study of using a laminar fluid diffusion interface for sample preparation in high-performance liquid chromatography"" (Journal of Chromatography A, 954 (2002) 33-40)",DISCONTINUED
16,US,A1,US 2023/0029744 A1,019-019-862-047-137,2023-02-02,2023,US 202117387279 A,2021-07-28,US 202117387279 A,2021-07-28,INTRACRANIAL DIAGNOSTICS USING OPTICAL IMAGING OF COHERENT LIGHT INTERFERENCE,"Coherent light (e.g., laser light) is emitted into a cranium through an optical fiber. A tissue sample (e.g., red blood cells, blood vessels, brain tissue) within the cranium diffuses the coherent light. Different tissue sample motion quantities generate different coherent light interference patterns. An image of a coherent light interference pattern is captured with an image sensor coupled to an optical element. The speckle contrast of the image quantifies coherent light interference pattern. A waveform of sequentially captured speckle contrast values over time has characteristics that reflect intracranial blood flow health. If waveform characteristics indicate poor or questionable intracranial blood flow heath, a notification message is displayed, played, or otherwise transmitted.",OPEN WATER INTERNET INC,KONECKY SOREN;;HARTL BRAD;;GRAMA KEDAR;;ACHROL ACHAL SINGH,OPEN WATER INTERNET INC (2021-08-10),https://lens.org/019-019-862-047-137,Patent Application,yes,0,0,2,2,0,G06V40/145;;G06V40/15;;A61B5/0042;;A61B5/0066;;G06T7/0016;;G06T2207/10016;;G06T2207/30104;;G06T7/246;;G06T2207/30016;;A61B5/0042;;G06T7/0016;;G06T7/20;;A61B2576/026;;A61B5/0261;;G06T2207/30104;;G06T2207/10016;;G08B7/06;;G06V10/147,A61B5/00;;A61B5/026;;G06T7/00;;G06T7/20;;G08B7/06,,0,0,,,,PENDING
17,WO,A1,WO 2023/009974 A1,151-642-194-277-18X,2023-02-02,2023,US 2022/0074079 W,2022-07-22,US 202117387279 A,2021-07-28,INTRACRANIAL DIAGNOSTICS USING OPTICAL IMAGING OF COHERENT LIGHT INTERFERENCE,"Coherent light (e.g., laser light) is emitted into a cranium through an optical fiber. A tissue sample (e.g., red blood cells, blood vessels, brain tissue) within the cranium diffuses the coherent light. Different tissue sample motion quantities generate different coherent light interference patterns. An image of a coherent light interference pattern is captured with an image sensor coupled to an optical element. The speckle contrast of the image quantifies coherent light interference pattern. A waveform of sequentially captured speckle contrast values over time has characteristics that reflect intracranial blood flow health. If waveform characteristics indicate poor or questionable intracranial blood flow heath, a notification message is displayed, played, or otherwise transmitted.",OPEN WATER INTERNET INC,KONECKY SOREN;;HARTL BRAD;;GRAMA KEDAR;;ACHROL ACHAL SINGH,,https://lens.org/151-642-194-277-18X,Patent Application,yes,3,0,2,2,0,G06V40/145;;G06V40/15;;A61B5/0042;;A61B5/0066;;G06T7/0016;;G06T2207/10016;;G06T2207/30104;;G06T7/246;;G06T2207/30016;;A61B5/0042;;G06T7/0016;;G06T7/20;;A61B2576/026;;A61B5/0261;;G06T2207/30104;;G06T2207/10016;;G08B7/06;;G06V10/147,A61B8/00;;A61B5/00,,0,0,,,,PENDING
18,WO,A3,WO 2023/180811 A3,058-904-015-981-742,2023-11-23,2023,IB 2023000168 W,2023-03-22,US 202263322617 P,2022-03-22,MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES,"The disclosure relates, in part, to targeted drug delivery using an ultrasound procedure and, more particularly, to systems and methods for the measurement of levels of drug delivery and certain aspects of metabolism, such as drug metabolism, in the brain tissue.",INSIGHTEC LTD,PLAKSIN MICHAEL;;LEVY YOAV;;DE PICCIOTTO RAFI;;ACHROL ACHAL SINGH,,https://lens.org/058-904-015-981-742,Search Report,yes,4,0,2,2,0,A61B17/22004;;A61M37/0092;;A61B2017/22027;;A61N2007/0078;;A61N2007/0086;;A61N2007/0095;;A61N2007/0073;;A61N2007/0065;;A61N2007/0047;;A61N2007/0039,A61M37/00;;A61B17/00;;A61B17/22;;A61N7/00,,0,0,,,,PENDING
19,WO,A2,WO 2023/180811 A2,171-395-873-290-386,2023-09-28,2023,IB 2023000168 W,2023-03-22,US 202263322617 P,2022-03-22,MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES,"The disclosure relates, in part, to targeted drug delivery using an ultrasound procedure and, more particularly, to systems and methods for the measurement of levels of drug delivery and certain aspects of metabolism, such as drug metabolism, in the brain tissue.",INSIGHTEC LTD,PLAKSIN MICHAEL;;LEVY YOAV;;DE PICCIOTTO RAFI;;ACHROL ACHAL SINGH,,https://lens.org/171-395-873-290-386,Patent Application,yes,5,0,2,2,0,A61B17/22004;;A61M37/0092;;A61B2017/22027;;A61N2007/0078;;A61N2007/0086;;A61N2007/0095;;A61N2007/0073;;A61N2007/0065;;A61N2007/0047;;A61N2007/0039,,,8,6,075-948-782-995-337;;058-495-569-216-87X;;034-833-722-718-170;;049-682-682-393-664;;099-088-634-981-690;;024-169-891-620-048,10.1074/jbc.m109.067975;;20110364;;pmc2856260;;pmc9092835;;10.1186/s12987-022-00329-9;;35546671;;pmc7890078;;33613412;;10.3389/fneur.2020.577312;;6505548;;21445240;;pmc3060798;;10.1371/journal.pone.0014768;;10.3390/molecules25030482;;pmc7038198;;31979301,"""Nonlinear ΔRZ Effects in Perfusion Quantification Using Bolus-Tracking MRI"", MAG. RES. IN MEDICINE, vol. 61, 2009, pages 486 - 492;;TANG ET AL.: ""Oligomers of Mutant Glial Fibrillary Acidic Protein (GFAP) Inhibit the Proteasome System in Alexander Disease Astrocytes, and the Small Heat Shock Protein aB-Crystallin Reverses the Inhibition"", J BIOL CHEM, vol. 285, no. 14, 2010, pages 10527 - 10537;;MURCKO ET AL.: ""Diagnostic biomarker kinetics: how brain-derived biomarkers distribute through the human body, and how this affects their diagnostic significance: the case of S100B"", FLUIDS BARRIERS CNS, vol. 19, 2022, pages 32;;JANIGRO ET AL.: ""Peripheral Blood and Salivary Biomarkers of Blood-Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts"", FRONT NEUROL, vol. 11, 2021, pages 577312;;PAHLMAN ET AL.: ""Purification and characterization of human neuron-specific enolase: radioimmunoassay development"", TUMOUR BIOL, vol. 5, no. 2, 1984, pages 127 - 39;;THULIN ET AL.: ""Molecular determinants of S100B oligomer formation"", PLOS ONE, vol. 6, no. 3, 2011, pages e14768;;TANG ET AL.: ""Oligomers of Mutant Glial Fibrillary Acidic Protein (GFAP) Inhibit the Proteasome System in Alexander Disease Astrocytes, and the Small Heat Shock Protein aB-Crystallin Reverses the Inhibition"", J BIOL CHEM., vol. 285, no. 14, 2010, pages 10527 - 10537;;CYBULSKA ET AL.: ""Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers"", MOLECULES, vol. 25, no. 3, 2020, pages 482, XP055782058, DOI: 10.3390/molecules25030482",PENDING
20,US,A1,US 2023/0293913 A1,041-552-883-577-420,2023-09-21,2023,US 202318122126 A,2023-03-16,US 202318122126 A;;US 202263321056 P,2022-03-17,HARMONIC EXCITATION THERAPY AND ANTI-TUMOR AGENT,An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the patient. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage the tumor while the anti-tumor agent has increased the susceptibility of the tumor to the harmonic excitation of the therapeutic ultrasound signal.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/041-552-883-577-420,Patent Application,yes,0,0,3,6,0,A61N2007/0078;;A61N7/00;;A61B34/10;;A61N7/00;;A61B8/08;;A61N2007/0073;;A61N2007/0004;;A61N2007/0078;;A61B8/5223,A61B8/08;;A61N7/00,,0,0,,,,PENDING
21,WO,A2,WO 2023/178331 A2,153-529-141-558-592,2023-09-21,2023,US 2023/0064663 W,2023-03-17,US 202263321056 P;;US 202318122126 A,2022-03-17,HARMONIC EXCITATION THERAPY AND ANTI-TUMOR AGENT,An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the patient. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage the tumor while the anti-tumor agent has increased the susceptibility of the tumor to the harmonic excitation of the therapeutic ultrasound signal.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/153-529-141-558-592,Patent Application,yes,0,0,3,6,0,A61N2007/0078;;A61N7/00;;A61B34/10;;A61N7/00;;A61B8/08;;A61N2007/0073;;A61N2007/0004;;A61N2007/0078;;A61B8/5223,A61N7/00;;A61K41/00,,0,0,,,,PENDING
22,WO,A3,WO 2023/178331 A3,086-373-781-677-85X,2023-11-02,2023,US 2023/0064663 W,2023-03-17,US 202263321056 P;;US 202318122126 A,2022-03-17,HARMONIC EXCITATION THERAPY AND ANTI-TUMOR AGENT,An anti-tumor agent is provided to a patient to increase a susceptibility of a tumor within the patient to harmonic excitation. Ultrasonic transducers of a wearable are driven to direct a therapeutic ultrasound signal into tissue of the patient. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage the tumor while the anti-tumor agent has increased the susceptibility of the tumor to the harmonic excitation of the therapeutic ultrasound signal.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/086-373-781-677-85X,Search Report,yes,4,0,3,6,0,A61N2007/0078;;A61N7/00;;A61B34/10;;A61N7/00;;A61B8/08;;A61N2007/0073;;A61N2007/0004;;A61N2007/0078;;A61B8/5223,A61M37/00;;A61N7/00;;H04R17/00,,0,0,,,,PENDING
23,WO,A2,WO 2023/178330 A2,170-314-461-337-156,2023-09-21,2023,US 2023/0064662 W,2023-03-17,US 202263321056 P;;US 202318122124 A,2022-03-17,HARMONIC EXCITATION TISSUE THERAPY,One or more ultrasonic transducers are driven to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage abnormal tissue but not harmonically excite healthy tissue.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/170-314-461-337-156,Patent Application,yes,0,0,3,6,0,A61N7/00;;A61N2007/0078;;A61N2007/003;;A61N7/00;;A61N2007/0078;;A61N2007/0086;;A61N2007/0056;;A61N2007/0052,A61N7/00,,0,0,,,,PENDING
24,US,A1,US 2023/0149744 A1,166-200-988-571-539,2023-05-18,2023,US 202217986721 A,2022-11-14,US 202217986721 A;;US 202263404407 P;;US 202163279789 P,2021-11-16,THERAPEUTIC INHIBITION AND STIMULATION WITH TRANSCRANIAL ULTRASOUND,A health message is received. At least one target brain region is selected in response to receiving the health message. An ultrasound modality profile based on the health message and the at least one target brain region is generated. A wearable therapeutic ultrasound device directs the ultrasound beams to the at least one target brain region in response to the health message. The ultrasound beams are driven with the ultrasound beam profile.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;ORNELLAS SARAH BARRETO;;TASKIN ULAS,OPEN WATER INTERNET INC (2022-11-29),https://lens.org/166-200-988-571-539,Patent Application,yes,0,1,2,2,0,A61N7/00;;A61N2007/0026;;A61N2007/0078;;A61N2007/0095;;A61N2007/0021;;A61N7/00;;A61N2007/0078;;A61N2007/0026,A61N7/00,,0,0,,,,PENDING
25,WO,A1,WO 2023/091969 A1,009-451-967-728-940,2023-05-25,2023,US 2022/0079988 W,2022-11-16,US 202163279789 P;;US 202263404407 P;;US 202217986721 A,2021-11-16,THERAPEUTIC INHIBITION AND STIMULATION WITH TRANSCRANIAL ULTRASOUND,A health message is received. At least one target brain region is selected in response to receiving the health message. An ultrasound modality profile based on the health message and the at least one target brain region is generated. A wearable therapeutic ultrasound device directs the ultrasound beams to the at least one target brain region in response to the health message. The ultrasound beams are driven with the ultrasound beam profile.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;ORNELLAS SARAH BARRETO;;HARTL BRAD A;;TASKIN ULAS,,https://lens.org/009-451-967-728-940,Patent Application,yes,4,0,2,2,0,A61N7/00;;A61N2007/0026;;A61N2007/0078;;A61N2007/0095;;A61N2007/0021;;A61N7/00;;A61N2007/0078;;A61N2007/0026,A61N2/00;;A61N7/00;;A61N2/02,,3,3,053-394-761-192-906;;026-597-195-538-896;;006-700-178-639-545,pmc8309087;;34371696;;10.3390/pharmaceutics13071002;;32477055;;pmc7235408;;10.3389/fnins.2020.00445;;pmc8507972;;10.3389/fnhum.2021.749162;;34650419,"GÖTZ JÜRGEN, RICHTER-STRETTON GINA, CRUZ ESTEBAN: ""Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer’s Disease"", PHARMACEUTICS, vol. 13, no. 7, pages 1002, XP093069991, DOI: 10.3390/pharmaceutics13071002;;YANG HUIFANG, YUAN YI, WANG XINGRAN, LI XIN: ""Closed-Loop Transcranial Ultrasound Stimulation for Real-Time Non-invasive Neuromodulation in vivo"", FRONTIERS IN NEUROSCIENCE, vol. 14, XP093069992, DOI: 10.3389/fnins.2020.00445;;ZHANG TINGTING, PAN NA, WANG YUPING, LIU CHUNYAN, HU SHIMIN: ""Transcranial Focused Ultrasound Neuromodulation: A Review of the Excitatory and Inhibitory Effects on Brain Activity in Human and Animals"", FRONTIERS IN HUMAN NEUROSCIENCE, vol. 15, XP093069994, DOI: 10.3389/fnhum.2021.749162",PENDING
26,WO,A3,WO 2023/178332 A3,112-581-360-698-043,2023-11-23,2023,US 2023/0064665 W,2023-03-17,US 202263321060 P;;US 202318121474 A,2022-03-17,CLOTLYSIS FROM ULTRASONIC HARMONIC EXCITATION,"A therapy system comprising: one or more ultrasonic emitters disposed to direct a therapeutic ultrasound signal into a tissue; and processing logic configured to drive the one or more ultrasonic emitters, wherein the therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite blood clots to liquify the blood clot to become soluble to blood flowing through the tissue.",OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/112-581-360-698-043,Search Report,yes,5,0,3,3,0,A61B17/22004;;A61B2017/00057;;A61N7/00;;A61N2007/0021;;A61N2007/0078;;A61B17/22004;;A61B2017/00057;;A61B2090/502,A61B17/22;;A61H23/02;;A61N7/00,,0,0,,,,PENDING
27,US,A1,US 2023/0293912 A1,054-093-467-411-183,2023-09-21,2023,US 202318122124 A,2023-03-16,US 202318122124 A;;US 202263321056 P,2022-03-17,HARMONIC EXCITATION TISSUE THERAPY,One or more ultrasonic transducers are driven to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage abnormal tissue but not harmonically excite healthy tissue.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/054-093-467-411-183,Patent Application,yes,0,0,3,6,0,A61N7/00;;A61N2007/0078;;A61N2007/003;;A61N7/00;;A61N2007/0078;;A61N2007/0086;;A61N2007/0056;;A61N2007/0052,A61N7/00,,0,0,,,,PENDING
28,WO,A3,WO 2023/178330 A3,028-669-103-951-150,2023-12-07,2023,US 2023/0064662 W,2023-03-17,US 202263321056 P;;US 202318122124 A,2022-03-17,HARMONIC EXCITATION TISSUE THERAPY,"A therapy system comprising: a wearable article including one or more ultrasonic transducers; and processing logic configured to drive the one or more ultrasonic transducers to direct a therapeutic ultrasound signal into tissue brought into contact with the ultrasonic transducers, wherein the therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite and damage abnormal tissue but not harmonically excite healthy tissue, wherein the one or more ultrasonic transducers are configured to direct the therapeutic ultrasound signal to propagate through the abnormal tissue and the healthy tissue.",OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/028-669-103-951-150,Search Report,yes,5,0,3,6,0,A61N7/00;;A61N2007/0078;;A61N2007/003;;A61N7/00;;A61N2007/0078;;A61N2007/0086;;A61N2007/0056;;A61N2007/0052,A61N7/00;;A61B5/00;;A61B8/00;;B06B1/02;;G10K11/34,,0,0,,,,PENDING
29,US,A1,US 2023/0293193 A1,112-284-742-036-503,2023-09-21,2023,US 202318121474 A,2023-03-14,US 202318121474 A;;US 202263321060 P,2022-03-17,CLOTLYSIS FROM ULTRASONIC HARMONIC EXCITATION,A wearable device includes one or more ultrasonic emitters disposed to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite blood clots to liquify the blood clot to become soluble to blood flowing through the head.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/112-284-742-036-503,Patent Application,yes,0,0,3,3,0,A61B17/22004;;A61B2017/00057;;A61N7/00;;A61N2007/0021;;A61N2007/0078;;A61B17/22004;;A61B2017/00057;;A61B2090/502,A61B17/22,,0,0,,,,PENDING
30,WO,A2,WO 2023/178332 A2,134-200-318-648-487,2023-09-21,2023,US 2023/0064665 W,2023-03-17,US 202263321060 P;;US 202318121474 A,2022-03-17,CLOTLYSIS FROM ULTRASONIC HARMONIC EXCITATION,A wearable device includes one or more ultrasonic emitters disposed to direct a therapeutic ultrasound signal into tissue. The therapeutic ultrasound signal has a resonant ultrasound frequency to harmonically excite blood clots to liquify the blood clot to become soluble to blood flowing through the head.,OPEN WATER INTERNET INC,ACHROL ACHAL SINGH;;KONECKY SOREN;;BAWIEC CHRISTOPHER R;;HARTL BRAD A;;TASKIN ULAS;;ORNELLAS SARAH BARRETO,,https://lens.org/134-200-318-648-487,Patent Application,yes,0,0,3,3,0,A61B17/22004;;A61B2017/00057;;A61N7/00;;A61N2007/0021;;A61N2007/0078;;A61B17/22004;;A61B2017/00057;;A61B2090/502,A61N7/00,,0,0,,,,PENDING
